Sangivamycin is a cytotoxic purine nucleoside active against human cytomegalovirus (HCMV). Sangivamycin is also a selective and potent PKC (protein kinase C) inhibitor (IC50 = 10μM). The inhibition is competitive with respect to ATP and non-competitive with respect to histone and lipid cofactors. The phosphorylation of histone H1 protein is a mechanism by which Sangivamycin prevents the cell growth and acts as cytotoxic agent against a variety of human cancers.
1. Turk, S R., et al., 1987. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrobial agents and chemotherapy. 31(4): 544-50. PMID: 3037998
2. Loomis, C R., et al., 1988. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. The Journal of biological chemistry. 263(4): 1682-92. PMID: 3338987
3. Greene, N M., et al., 1995. Kinetics and localization of the phosphorylation of rhodopsin by protein kinase C. The Journal of biological chemistry. 270(12): 6710-7. PMID: 7896814
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.